There was no significant difference between patient and control groups regarding the frequency of the GG polymorphism (P=1.000) or the frequency of GA polymorphism (P=1.000) (Table 7).
CHD shows high and increasing rates of morbidity and mortality 2, and its development involves hyperplasia of arterial smooth muscles, the presence of fatty streaks, atheroma formation, plaque rupture, thrombus formation, and vessel occlusion 4. The blood coagulation system is thought to determine the onset of MI through its role in blood clot formation. Searching for genetic variations that may affect this sequential mechanism may be very important for the prediction of the disease occurrence and/or prognosis 5.
Many epidemiological studies have identified the plasma fibrinogen level as a powerful predictor of future CHD. However, fibrinogen is also an acute-phase reactant, and in recent years, the evidence for inflammation as a cause of vascular disease has steadily grown. Investigators have therefore frequently turned to genetic studies that have the potential to provide evidence supporting a pathogenic role of fibrinogen in ischemic heart disease. If genetic polymorphisms causing elevated levels of fibrinogen were shown to be associated with an increased risk of ischemic heart disease, then this would be good evidence for fibrinogen playing a causal role in the disease 15.
However, despite the clear association between fibrinogen levels and ischemic heart disease in both prospective and cross-sectional studies, and the consistent association between genetic polymorphisms of the β-chain and fibrinogen levels, none of the large population-based studies have shown an association between the polymorphisms and ischemic heart disease 8.
Carriers of the A allele of the FGB-455 G/A polymorphism have increased plasma fibrinogen levels, and studies on this polymorphism have been performed mainly among Caucasians. The association between FGB-455 G/A polymorphism and thrombophilic diseases, such as venous thromboembolism and CHD, in the Chinese Han population had been investigated and the presence of the A allele was found to be a greater risk factor in cases than in controls 16.
The present study aimed at elucidating the association of FGB-455 G/A polymorphism with CHD in Egyptian patients. The FGB-455 G/G wild-type polymorphism was found to be the most frequent among the studied CHD Egyptian patients (66.67%) and the control persons (80%). Although it was found to be more likely associated with CHD in Egypt (OR<1); yet, there was no significant difference between the patient group and the control group regarding its frequency (P=0.243).
FGB-455 G/A was found to be less frequent than FGB-455 G/G among the studied CHD Egyptian patients (30%) and control persons (20%). Also, it was found to be less likely associated with CHD in Egypt (OR>1), and there was no significant difference between the patient group and the control group regarding its frequency (P=0.371). No significant difference was found between the patient group and the control group regarding the frequency of FGB-455 AA polymorphism (P=1.000), and it was found to be a rare polymorphism in the studied Egyptian participants (3.33% of the patient group and 0% of the control group). Thus, none of the polymorphisms of the FGB-455 locus differs significantly between patient and control groups (P-values >0.05). Accordingly, none of the three polymorphisms can be considered as a risk factor for CHD in the studied Egyptian population.
The results of this study were in agreement with Carty et al.1, who investigated whether common (≥5% minor allele frequency) variation in the fibrinogen genes (FGA, FGB, FGG) is associated with fibrinogen concentration variations, carotid artery intimal-medial thickening, and a risk of incident MI, ischemic stroke, and cardio vascular disease (CVD) mortality in European-American and African-American descent adults (≥65 years). They found that among European American, minor alleles of FGA3807, FGB1437 (which is FGB-455 G/A polymorphism), and FGG902 were associated with higher fibrinogen levels (P<0.004 for each). The strongest associations were seen for FGB1437; each additional copy of the minor allele was associated with a 13 mg/dl higher fibrinogen level 1. However, whereas fibrinogen genetic variation was strongly associated with fibrinogen levels, there was less evidence of an association with the more complex outcomes of intimal-medial thickening and CVD events 1.
Also Lu et al.17, studied the association between the genetic polymorphisms of the FGB gene and MI in the Chinese Han population. They found that the cases had significantly lower frequencies of FGB-455 G/A polymorphism than the controls; accordingly, they concluded that the FGB-455 G/A polymorphism was not associated with MI in the Chinese Han population after adjustment for the other traditional risk factors.
The most obvious possible explanation for a failure to find a relationship between genotype and disease is that fibrinogen plays no pathogenic role in coronary artery disease. In this scenario, fibrinogen acts as a marker of some other process, most probably inflammatory, which causes ischemic heart disease independently. This is supported by the finding that fibrinogen levels correlate closely with other acute-phase reactants in patients with ischemic heart disease, raising the possibility that fibrinogen is simply an indicator of disease rather than having a causal role 18. A second possible explanation is that fibrinogen does play a pathogenic role in ischemic heart disease, but the effect of genotype is small compared with other modifiers of fibrinogen level. Also, an effect of the genotype may be apparent only in conjunction with some other risk factor such as smoking or the acute-phase reaction and the presence of a polymorphic variation in genes for intermediaries such as IL-6, which is an inflammatory cytokine known to be the main regulator of fibrinogen synthesis 19.
Rather than directly affecting the levels of proteins or the risk of disease, polymorphisms can amplify the effect of environmental or intermediate conditions on the final phenotype. The genetic control of fibrinogen has to be considered together with the environmental factors: fibrinogen genotypes may interact with cigarette smoking, physical activity, use of drugs, hormonal status, and infections in determining the increase in fibrinogen levels and perhaps the risk of ischemic heart disease 20. Thus, in conclusion, it can be said that CVD events are the result of complex interactions among elevated fibrinogen level and cytokines, especially IL-6, which not only increase the fibrinogen level but also stimulate other events incorporated in the CHD pathogenesis such as vascular smooth muscles proliferation and the inflammatory nature of atherosclerotic plaques formation 21,22.
However, the present study does have some limitations. First, the lack of an association between the FGB-455 G/A polymorphism and MI may be due to the relatively small sample size. Second, the study participants were not recruited prospectively. Thus, a selection bias could not be excluded. Another limitation is that the plasma levels of fibrinogen were not determined. However, a larger cohort will ultimately be required to confirm whether or not the results of the present study are reliable.
The results of the present study were opposed by Reiner et al.7 and Chen et al.8, in different studies on different populations, who linked FGB-455 G/A polymorphism with CHD through the effect of the genotype on the circulating fibrinogen level. Reiner et al.7 analyzed the association between common polymorphisms in the fibrinogen genes and the circulating levels of both functional fibrinogen and total fibrinogen in a large, multicenter, biracial cohort of young US adults in European-American and African-American populations, and reported that a common haplotype tagged by the A minor allele of the well-studied FGB-455 G/A promoter polymorphism was confirmed to be strongly associated with increased plasma fibrinogen levels, which is a strong risk factor for the development of CHD. However, Chen et al.8 evaluated the correlation between FGB-455 G/A polymorphism and susceptibility to coronary artery disease in the Chinese population using a meta-analytic approach and found that the combined OR for the nine studies on the susceptibility to coronary artery disease in FGB-455 A allele carriers (G/A and A/A) compared with the FGB-455 G/G wild-type homozygote was 1.75, suggesting the possibility that FGB-455 G/A polymorphism (in particular, allele A) increases the susceptibility to CHD in the Chinese population.
Also, the results of the present study oppose the results of a similar study conducted by Dilley et al.23, who focused on the evaluation of the relationship between Legg–Perthes disease and the FGB-455 G/A polymorphism. Legg-Perthes disease is a pediatric hip disorder characterized by avascular necrosis of the femoral head, and its etiology involves repeated interruptions of the blood supply to the proximal femur. Accordingly, the role of thrombosis in the disease is of interest. They found that individuals who possessed either the G/A or the A/A genotype were over three times more likely to have Legg-Perthes disease compared with those without the polymorphism 23.
Several studies have shown that the A allele of the FGB-455 G/A polymorphism is associated with an elevated plasma fibrinogen concentration and that A instead of G in the FGB-455 position produces a 1.2–1.5-fold increase in the FGB transcription 24–28. The β-chain transcription is a rate-limiting step in the synthesis of the total functional fibrinogen molecule. Increased viscosity and a higher available substrate quantity resulting from an elevated plasma fibrinogen concentration may promote coagulation and act as a risk for small-vessel thrombotic occlusion, thus affecting the phenotype of the cerebral infarction. The results of the study conducted by Martiskainen et al.29, to assess the fibrinogen gene promoter-455 A Allele as a risk factor for lacunar stroke, concluded that stroke patients carrying the A allele of the FGB-455 G/A polymorphism frequently presented with multiple lacunar infarcts, and this association suggests that the A allele may predispose to atherothrombotic events in the cerebrovascular circulation. Their explanation was that the A genotype and the resulting increased fibrinogen concentration in circulation may contribute to the progression of arteriosclerosis, primarily in smaller cerebral arteries with slower blood flow rather than in large vessels 30. In this way, it may predispose one to the development of occlusions in small cerebral arteries and finally to multiple lacunar infarcts 29. Accordingly, the previous studies that oppose the results of the present study can explain their findings.
Inherited abnormalities of the hemostatic system that may predispose one to thrombosis are termed as inherited thrombophilias. One of them is PT 20210 G/A mutation, the prevalence of which in the general population is estimated to be 2.3% for its heterozygous form. However, this mutation is very rare in China. It implies that the variant of the PT gene is probably not the main cause of the thrombophilic diseases, such as venous thromboembolism and CHD, in the Chinese population 16.
PT 20210 G/A polymorphism has also been investigated in the present study, but current evidence does not support the hypothesis that this polymorphism might be a risk factor for CHD. PT 20210 G/A polymorphism was found to be rare among the studied CHD Egyptian patients (3.33%) and absent in the control persons. There was no significant difference between patient and control groups regarding its frequency (P=1.000). Although PT 20210 G/G wild-type was predominant among CHD Egyptian patients (96.67%) and control persons (100%), there was no significant difference between the patient and the control groups regarding its frequency (P=1.000). Although it was found that PT 20210 G/G is more likely to be associated with CHD (relative risk >1) and PT 20210 G/A is less likely to be associated with CHD (relative risk<1), neither polymorphism differs significantly between the patient and the control groups (P-value>0.05). Accordingly, neither polymorphism can be considered as a risk factor for CHD in the Egyptian population studied.
The results of the present study are in agreement with Rahimi et al.31, who assessed the contribution of factor V Leiden 1691 G/A, PT gene 20210 G/A, and methylentetrahydrofolate reductase (MTHFR) 677 C/T mutations in the development of CHD and their association with diabetes. Their results indicated that there was no significant difference between the prevalence of thrombophilic mutations of factor V Leiden, PT 20210 G/A variant, and MTHFR 677 C/T in CHD patients with or without diabetes compared with controls. Also, Özmen et al.32 failed to show any relation between PT gene mutation and increased risk of arterial thrombosis in their study that investigated the prevalence rates of factor V, MTHFR, and PT gene mutations in patients with arterial thrombosis and in healthy controls. Their findings suggested the MTHFR mutation as a synergistic risk factor for thrombosis in patients with factor V mutation, whereas PT gene mutation has no effect on arterial thrombosis as there was only one patient in their study with PT mutation, who was negative for the other two mutations. Thus, it can be proposed that this type of polymorphism may be harmless when alone, but may increase the risk for CHD when associated with other gene(s) polymorphisms. Also, Geng et al.33, in their study to determine whether polymorphisms in the genes for coagulation factors II, V, and VII could predispose an individual to an increased risk of CHD and/or MI in the Chinese, found that factor II (20210 G/A), V (1691 G/A) mutation is absent and may not be a major genetic factor for CHD and/or MI.
Almawi et al.34 studied factor V 1691 G/A, PT 20210 G/A, and MTHFR 677 C/T gene polymorphism in angiographically documented CHD; the results from this study clearly demonstrated a strong association of hyperhomocysteinemia and homozygosity of the MTHFR 677 C/T, but not factor V Leiden or PT 20210 G/A, mutations with confirmed CHD, which is consistent with our results. A mutation in the PT gene was identified to be associated with increased PT levels, but CHD development requires more complex interactions among several risk factors 35.
The results of the present study were opposed by Mugnolo et al.36, who reported a case of MI at a young age in a person with a medical history of repeated thrombophlebitis, who was heterozygous for the PT 20210 G/A mutation and homozygous for factor V Leiden mutation. A coronary angiography revealed the presence of a moderate atherosclerotic plaque (60%) in the left anterior descending coronary artery, which gave rise to suspicion of a relationship between prothrombotic gene mutations and atherosclerosis. Accordingly, they recommended that the genetic screening for inherited thrombophilia, especially in the presence of a strong familiarity or previous venous thrombosis, and the evaluation of atherosclerotic risk factors, may be critical information for primary prevention of arterial thrombosis 36.
Also, Ye et al.37 performed a meta-analysis on seven hemostatic gene polymorphisms in CHD patients; one of them was PT 20210 G/A. The study involved a total of 66 155 CHD cases and 91 307 controls. Their results, which oppose the results of the present study, concluded that the 20210 A variant of the PT gene increases circulating thrombin generation and might be moderately associated with the risk of CHD 37. Thus, whether PT 20210 G/A mutation could be considered as a risk factor for CHD or not remains controversial although it was established that this mutation increases the amount of PT in the blood stream. It is not yet fully understood as to how increased levels of PT act as a risk factor for CHD, but some studies have indicated that extra PT may interfere with the body's natural ability to dissolve clots. About 1–2% of people with European ancestry carry the PT 20210 G/A mutation 38.
However, in the present study, the lipid profile of the patients was significantly higher than that of the controls (P-values=0.00), which ensures the concept that atherosclerosis and CHD are more related to the elevation in serum cholesterol, triglycerides, and the LDL-cholesterol/HDL-cholesterol ratio in addition to an unhealthy lifestyle 39,40. Alber et al.41 investigated the relationship between HDL cholesterol and the prevalence and severity of coronary artery disease (CHD) in 5641 consecutive patients undergoing coronary angiography. They found that HDL-cholesterol was significantly higher in non-CHD persons than in CHD patients (P<0.001). Accordingly, they concluded that HDL-cholesterol is a stronger predictor of CHD than some other major classical risk factors 41. Furthermore, the results of the present study showed a nonsignificant difference between patients and controls with regard to the age (P=0.120) and sex distribution (P=0.307), which again potentiates the value of the significant lipid profile difference between patients and control persons over other traditional risk factors such as age and sex.
Although the present study was conducted on CHD Egyptian patients, yet, its results may be applicable to other CVDs such as lacunar stroke and peripheral arterial ischemia 29,30. This is due to the similar pathogenesis of the diseases and similar involvement of the two genes of the study. This is similar with the results of Banerjee et al.30, who stated that the plasma fibrinogen level is a valuable index for the peripheral arterial ischemia patients with stable intermittent claudications and a high risk of early mortality. Their results also provide further evidence for the involvement of fibrinogen in the pathogenesis of ischemic arterial diseases 30. Also, a meta-analysis, where 41 publications that examined 44 gene polymorphisms were included, was performed by Elias Zintzaras and Nikos Zdoukopoulos 42, on the basis of the similarity among ischemic arterial diseases in the pathophysiological pathways. FGB-455 G/A and PT 20210 G/A polymorphisms were included in that study, and the results concluded that their association with peripheral arterial ischemia remains controversial 42.
Although a specific genotype may be associated, in healthy participants, with modest differences in the levels of a risk factor for thrombosis, this effect may be larger or smaller in subgroups of participants. Documenting such gene–environment interactions is important if genotype information is ever to be used in a clinical or diagnostic setting. Understanding the molecular mechanisms of such interactions is very important for the development of novel therapeutic approaches to reduce the risk of MI. Future studies should be designed specifically to investigate interactions between potential genetic polymorphisms and acquired risk factors.
Conflicts of interest
There are no conflicts of interest.
1. Carty CL, Cushman M, Jones D, Lange LA, Hindorff LA, Rice K, et al. Associations between common fibrinogen gene polymorphisms and cardiovascular disease in older adults: the cardiovascular health study. Thromb Haemost. 2008;99:388–395
2. Lloyd Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics – 2010 update: a report from the american heart association. Circulation. 2010;121:e46–e215
3. Varga EA, Moll S. Cardiology patient pages. Prothrombin 20210 mutation (factor II mutation). Circulation. 2004;110:e15–e18
4. McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV, Troxclair DA, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 2000;20:1998–2004
5. Rosendaal FR. Clotting and myocardial infarction: a cycle of insights. J Thromb Haemost. 2003;1:640–642
6. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005;115:3355–3362
7. Reiner AP, Carty CL, Carlson CS, Wan JY, Rieder MJ, Smith JD, et al. Association between patterns of nucleotide variation across the three fibrinogen genes and plasma fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Thromb Haemost. 2006;4:1279–1287
8. Chen X, Xu M, Jin L, Chen J, Chen W. Association of β-fibrinogen gene-148C/T and -455 G/A polymorphisms and coronary artery disease in Chinese population: a meta analysis. SciChina C Life Sci. 2008;51:814–820
9. Green FR. Fibrinogen polymorphisms and atherothrombotic disease. Ann N Y Acad Sci. 2001;936:549–559
10. Frances F, Portoles O, Gabriel F, Corella D, Sorli JV, Sabater A, et al. Factor V Leiden (G1691A) and prothrombin-G20210A alleles among patients with deep venous thrombosis and in the general population from Spain. Rev Med Chil. 2006;134:13–20
11. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517–1532
12. Sykes TC, Fegan C, Mosquera D. Thrombophilia, polymorphisms and vascular disease. MolPathol. 2000;53:300–306
13. Franco RF, Reitsma PH. Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol. 2001;115:491–506
14. Norman N, Bent D, Hull CH. SPSS: Statistical Package for the Social Sciences. New York: McGraw-Hill, 1970
15. Blake GJ, Schmitz C, Lindpaintner K, Ridker PM. Mutation in the promoter region of the beta-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis. Eur Heart J. 2001;22:2262–2266
16. Zhai ZG, Zhan X, Yang YH, Wang C. Recent research on venous thromboembolism in China: a brief report from China Venous Thromboembolism Study Group. Chin Med J. 2010;123:485–490
17. Lu XF, Yu HJ, Zhou XY, Wang LY, Huang JF, Gu DF. Influence of fibrinogen β-chain gene variations on risk of myocardial infarction in a Chinese Han population. Chin Med J. 2008;121:1549–1553
18. Gardemann A, Schwartz O, Haberbosch W, Katz N, Weiss T, Tillmanns H, et al. Positive association of the beta fibrinogen H1/H2 gene variation to basal fibrinogen levels and to the increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost. 1997;77:1120–1126
19. Carty CL, Heagerty P, Heckbert SR, Jarvik GP, Lange LA, Cushman M, et al. Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the cardiovascular health study. Ann Hum Genet. 2010;74:1–10
20. Vischetti M, Zito F, Donati MB, Iacoviello L. Analysis of gene-environment interaction in coronary heart disease: Fibrinogen polymorphisms as an example. Ital Heart J. 2002;3:18–23
21. Theodoraki EV, Nikopensius T, Suhorutšenko J, Peppes V, Fili P, Kolovou G, et al. Fibrinogen beta variants confer protection against coronary artery disease in a Greek case–control study. BMC Med Genet. 2010;11:28–34
22. Mannila MN, Eriksson P, Leander K, Wiman B, de Faire U, Hamsten A, et al. The association between fibrinogen haplotypes and myocardial infarction in men is partly mediated through pleiotropic effects on the serum IL-6 concentration. J Intern Med. 2007;261:138–147
23. Dilley A, Hooper WC, Austin H, Jamil M, Miller C, Stokes M, et al. The beta fibrinogen gene G-455-A polymorphism is a risk factor for Legg–Perthes disease. J Thromb Haemost. 2003;1:2317–2321
24. Humphries SE, Ye S, Talmud P, Bara L, Wilhelmsen L, Tiret L. European Atherosclerosis Research Study: genotype at the fibrinogen locus (G-455-A beta-gene) is associated with differences in plasma fibrinogen levels in young men and women from different regions in Europe. Evidence for gender–genotype–environment interaction. Arterioscler Thromb Vasc Biol. 1995;15:96–104
25. Green F, Hamsten A, Blomback M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost. 1993;70:915–920
26. Thomas AE, Green FR, Lamlum H, Humphries SE. The association of combined alpha and beta fibrinogen genotype on plasma fibrinogen levels in smokers and non-smokers. J Med Genet. 1995;32:585–589
27. Van’t Hooft FM, von Bahr SJ, Silveira A, Iliadou A, Eriksson P, Hamsten A. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol. 1999;19:3063–3070
28. Brown ET, Fuller GM. Detection of a complex that associates with the beta fibrinogen G-455-A polymorphism. Blood. 1998;92:3286–3293
29. Martiskainen M, Pohjasvaara T, Mikkelsson J, Mantyla R, Kunnas T, Laippala P, et al. Fibrinogen gene promoter-455 A allele as a risk factor for lacunar stroke. Stroke. 2003;34:886–891
30. Banerjee AK, Pearson J, Gilliland EL, Goss D, Lewis JD, Stirling Y, et al. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost. 1992;68:261–263
31. Rahimi Z, Nomani H, Mozafari H, Vaisi Raygani A, Madani H, Malek Khosravi S, et al. Factor v G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran. Blood Coagul Fibrinolysis. 2009;20:252–256
32. Özmen F, Özmen MM, Özalp N, Akar N. The prevalence of factor V (G1691A), MTHFR (C677T) and PT (G20210A) gene mutations in arterial thrombosis. Ulus Travma Acil Cerrahi Derg. 2009;15:113–119
33. Geng X, Jin GD, Fu GS, Ji MA, Shan J, Wang JA. Polymorphisms in the genes for coagulation factor II, V, VII in patients undergoing coronary angiography. J Zhejiang Univ Sci. 2003;4:369–373
34. Almawi WY, Ameen G, Tamim H, Finan RR, Irani Hakime N. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysis. 2004;17:199–205
35. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men. Circulation. 1999;99:999–1004
36. Mugnolo A, Toniolo M, Cicoira M, Vassanelli F, Vassanelli C. Myocardial infarction in a young patient with a previous history of repeated thrombophlebitis: combination of factor v Leiden and prothrombin G20210A gene polymorphisms with coronary artery disease. J Cardiovasc Med. 2010;11:125–126
37. Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls. Lancet. 2006;367:651–658
38. Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005;94:17–25
39. Ladeia AM, Guimaraes AC, Lima JC. The lipid profile and coronary artery disease. Arq Bras Cardiol. 1994;63:101–106
40. Yokus O, Albayrak M, Balcik OS, Ceran F, Dagdas S, Yilmaz M, et al. Risk factors for thrombophilia in young adults presenting with thrombosis. Int J Hematol. 2009;90:583–590
41. Alber HF, Wanitschek MM, De Waha S, Ladurner A, Suessenbacher A, Dörler J, et al. High-density lipoprotein cholesterol, C-reactive protein and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography. Eur J Clin Invest. 2008;38:372–380
© 2011 Medical Research Journal
42. Zintzaras E, Zdoukopoulos N. A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: the CUMAGAS-PAD database. Am J Epidemiol. 2009;170:1–11